Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression

@inproceedings{Huang2019DownregulationOK,
  title={Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression},
  author={Haipeng Huang and Yunhong Wu and Weijin Fu and Xiaoming Wang and Liquan Zhou and Xiaolong Xu and Fu Huang and Yi Wu},
  booktitle={International journal of molecular medicine},
  year={2019}
}
Kelch‑like ECH‑associated protein 1 (Keap1)/nuclear factor erythroid 2‑related factor 2 (Nrf2) signaling has a protective effect on normal cells. A number of previous studies demonstrated that Keap1/Nrf2 signaling is associated with drug resistance in numerous tumors. The aim of the present study was to investigate the roles of Keap1 in renal cell carcinoma (RCC) and its effect on sensitivity to chemotherapy. Reverse transcription‑quantitative polymerase chain reaction was used to detect the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 73 REFERENCES

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 2 EXCERPTS

Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiotherapy response prediction. cancer discovery

Y Jeong, NT Hoang, +7 authors A chaudhuri
  • 2017
VIEW 1 EXCERPT